Shelton Capital Management Upped Its Schein Henry (HSIC) Holding; 15 Analysts Covering bluebird bio, Inc. (BLUE)

January 13, 2018 - By Peter Erickson

Shelton Capital Management increased Schein Henry Inc (HSIC) stake by 100% reported in 2017Q3 SEC filing. Shelton Capital Management acquired 6,225 shares as Schein Henry Inc (HSIC)’s stock rose 5.77%. The Shelton Capital Management holds 12,450 shares with $1.02 million value, up from 6,225 last quarter. Schein Henry Inc now has $11.75 billion valuation. The stock increased 2.10% or $1.54 during the last trading session, reaching $74.84. About 1.05M shares traded. Henry Schein, Inc. (NASDAQ:HSIC) has risen 4.05% since January 13, 2017 and is uptrending. It has underperformed by 12.65% the S&P500.

Among 25 analysts covering bluebird bio (NASDAQ:BLUE), 15 have Buy rating, 2 Sell and 8 Hold. Therefore 60% are positive. bluebird bio had 79 analyst reports since August 11, 2015 according to SRatingsIntel. The company was maintained on Saturday, August 15 by Roth Capital. The stock of bluebird bio, Inc. (NASDAQ:BLUE) has “Sell” rating given on Friday, October 14 by Cantor Fitzgerald. Maxim Group maintained the shares of BLUE in report on Tuesday, January 5 with “Buy” rating. The stock of bluebird bio, Inc. (NASDAQ:BLUE) earned “Buy” rating by BTIG Research on Wednesday, May 31. The rating was maintained by SunTrust with “Buy” on Friday, November 3. The firm has “Buy” rating given on Wednesday, November 18 by Goldman Sachs. The stock has “Equal-Weight” rating by Morgan Stanley on Monday, August 7. BMO Capital Markets maintained the shares of BLUE in report on Monday, October 30 with “Outperform” rating. The stock has “Buy” rating by Roth Capital on Thursday, September 22. JP Morgan maintained bluebird bio, Inc. (NASDAQ:BLUE) rating on Saturday, August 22. JP Morgan has “Overweight” rating and $244 target. See bluebird bio, Inc. (NASDAQ:BLUE) latest ratings:

09/01/2018 Broker: Oppenheimer Rating: Hold Maintain
20/12/2017 Broker: Oppenheimer Rating: Hold Initiate
11/12/2017 Broker: Goldman Sachs Rating: Buy New Target: $309.0
13/12/2017 Broker: Maxim Group Old Rating: Buy New Rating: Hold Old Target: $200 Downgrade
13/12/2017 Broker: Barclays Capital Rating: Buy New Target: $209.0 Maintain
12/12/2017 Broker: Wells Fargo Rating: Buy New Target: $242.0 Maintain
11/12/2017 Broker: SunTrust Rating: Buy New Target: $223.0 Maintain
11/12/2017 Broker: J.P. Morgan Rating: Buy
11/12/2017 Broker: Jefferies Rating: Buy New Target: $211.0 Upgrade
11/12/2017 Broker: Cantor Fitzgerald Rating: Sell New Target: $113.0 Maintain

Investors sentiment increased to 1.79 in Q3 2017. Its up 0.11, from 1.68 in 2017Q2. It improved, as 35 investors sold bluebird bio, Inc. shares while 42 reduced holdings. 45 funds opened positions while 93 raised stakes. 49.05 million shares or 2.37% more from 47.91 million shares in 2017Q2 were reported. Clough Cap Prtnrs Limited Partnership reported 5,200 shares or 0.05% of all its holdings. Federated Investors Pa accumulated 18,371 shares. Rmb Capital Ltd Liability Com holds 0.07% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE) for 19,090 shares. Tower Rech Capital Ltd (Trc) reported 3,667 shares or 0.04% of all its holdings. Teachers Retirement Of The State Of Kentucky reported 0.05% in bluebird bio, Inc. (NASDAQ:BLUE). Hanseatic Mgmt Services accumulated 2,036 shares. Winslow Evans And Crocker Inc stated it has 3,800 shares. North Star Management Corp reported 150 shares. Moreover, Kazazian Asset Management Lc has 0.69% invested in bluebird bio, Inc. (NASDAQ:BLUE) for 4,083 shares. Balyasny Asset Mngmt Limited Liability Corp invested in 503,122 shares or 0.27% of the stock. Emerald Mutual Fund Advisers Trust reported 147,897 shares. 1832 Asset Mgmt Limited Partnership accumulated 207,300 shares. Tiaa Cref Limited Liability Co has invested 0.02% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE). Baker Bros Advsr L P invested in 0.27% or 241,441 shares. Columbus Circle Invsts holds 139,312 shares.

The stock decreased 0.55% or $0.95 during the last trading session, reaching $170.7. About 631,389 shares traded. bluebird bio, Inc. (NASDAQ:BLUE) has risen 112.34% since January 13, 2017 and is uptrending. It has outperformed by 95.64% the S&P500.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. The company has market cap of $8.37 billion. The Company’s product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. It currently has negative earnings. The companyÂ’s lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications.

Among 19 analysts covering Henry Schein Inc. (NASDAQ:HSIC), 11 have Buy rating, 1 Sell and 7 Hold. Therefore 58% are positive. Henry Schein Inc. had 42 analyst reports since July 31, 2015 according to SRatingsIntel. On Tuesday, January 3 the stock rating was upgraded by Robert W. Baird to “Outperform”. The firm has “Buy” rating given on Tuesday, November 7 by Craig Hallum. On Tuesday, November 7 the stock rating was maintained by Robert W. Baird with “Buy”. Stifel Nicolaus maintained Henry Schein, Inc. (NASDAQ:HSIC) on Wednesday, July 5 with “Hold” rating. The stock of Henry Schein, Inc. (NASDAQ:HSIC) has “Outperform” rating given on Thursday, November 5 by RBC Capital Markets. As per Tuesday, November 7, the company rating was maintained by Leerink Swann. The stock of Henry Schein, Inc. (NASDAQ:HSIC) earned “Buy” rating by Gabelli on Tuesday, January 10. The rating was maintained by Piper Jaffray on Tuesday, August 8 with “Hold”. The firm has “Hold” rating given on Tuesday, October 17 by Stifel Nicolaus. The stock of Henry Schein, Inc. (NASDAQ:HSIC) has “Hold” rating given on Tuesday, August 8 by Stifel Nicolaus.

Since September 6, 2017, it had 0 insider buys, and 1 sale for $366,756 activity. Rose Paul sold $366,756 worth of Henry Schein, Inc. (NASDAQ:HSIC) on Wednesday, September 6.

Shelton Capital Management decreased Chevron Corp New (NYSE:CVX) stake by 37,174 shares to 215,623 valued at $25.34M in 2017Q3. It also reduced Ishares Tr (IWM) stake by 2,800 shares and now owns 11,784 shares. Shire Plc (NASDAQ:SHPG) was reduced too.

Investors sentiment increased to 7.15 in Q3 2017. Its up 5.99, from 1.16 in 2017Q2. It increased, as 47 investors sold HSIC shares while 15 reduced holdings. 66 funds opened positions while 377 raised stakes. 279.70 million shares or 306.41% more from 68.82 million shares in 2017Q2 were reported. Interest Group Inc owns 56,236 shares. Lombard Odier Asset (Europe) invested in 2,464 shares or 0.01% of the stock. Security National Trust holds 0.14% or 5,290 shares in its portfolio. The Netherlands-based Robeco Institutional Asset Mgmt Bv has invested 0.01% in Henry Schein, Inc. (NASDAQ:HSIC). Palisade Mngmt Lc Nj accumulated 17,880 shares or 0.05% of the stock. Girard Prtnrs Limited invested in 6,640 shares. Moreover, Bank & Trust Of Mellon Corp has 0.03% invested in Henry Schein, Inc. (NASDAQ:HSIC) for 1.53 million shares. Tortoise Management Limited Liability Corp owns 1,398 shares or 0.03% of their US portfolio. Epoch Inv Prns owns 64,204 shares. Montecito Bancorp And Trust invested in 0.07% or 2,600 shares. Hsbc Public Limited Co holds 0.02% or 183,211 shares in its portfolio. Shell Asset Mgmt stated it has 0.22% of its portfolio in Henry Schein, Inc. (NASDAQ:HSIC). Strs Ohio holds 0.02% of its portfolio in Henry Schein, Inc. (NASDAQ:HSIC) for 59,555 shares. Moreover, First Republic Mgmt Inc has 0.01% invested in Henry Schein, Inc. (NASDAQ:HSIC) for 24,346 shares. Parkside Finance Financial Bank & Tru holds 0.02% or 604 shares in its portfolio.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>